Abstract
Immunotherapy has revolutionized clinical outcomes in both early-stage and advanced-stage malignancies. Immunotherapy has improved patient survival in both solid and hematologic disorders with the potential added benefit of less toxicity compared to conventional cytotoxic chemotherapy. Imaging plays a fundamental role in monitoring treatment response and assessment of immune-related adverse events, e.g. pneumonitis, colitis, etc. Familiarity with the current strategies of immune-related response evaluation and their limitations is essential for radiologists to guide clinicians with their treatment decisions. Radiologists should be aware of the wide spectrum of immune-related adverse events and their various radiological features as well as the patterns of treatment response associated with immunotherapies.
Original language | English (US) |
---|---|
Article number | 110062 |
Journal | European Journal of Radiology |
Volume | 146 |
DOIs | |
State | Published - Jan 2022 |
Keywords
- Imaging
- Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
- Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)
- Immune-related response criteria (irRC)
- Immunotherapy
- Response Evaluation Criteria in Solid Tumors
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging